Will NCATS Become More Than The Sum Of Its Parts?
Executive Summary
NCATS may be new, but most of its efforts to facilitate the search for methods and technologies to reduce the cost of drug development will be made through pre-existing funding and programs.
You may also be interested in...
FDA's Spielberg Wants NIH/FDA Collaborations To Focus On Problem-Solving
NIH research could help FDA overcome pressing scientific hurdles and provide a rational basis for regulatory decision-making, the agency's new deputy commissioner for medical products and tobacco tells the Alliance for a Stronger FDA.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.
Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters
EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.